110 related articles for article (PubMed ID: 23551674)
1. Why an apheresis center should offer more than one lipoprotein apheresis method.
Julius U; Fischer S; Schatz U; Passauer J; Bornstein S
Ther Apher Dial; 2013 Apr; 17(2):179-84. PubMed ID: 23551674
[TBL] [Abstract][Full Text] [Related]
2. Effects of two whole blood systems (DALI and Liposorber D) for LDL apheresis on lipids and cardiovascular risk markers in severe hypercholesterolemia.
Otto C; Berster J; Otto B; Parhofer KG
J Clin Apher; 2007; 22(6):301-5. PubMed ID: 17935245
[TBL] [Abstract][Full Text] [Related]
3. Intraindividual comparison of the impact of two selective apheresis methods (DALI and HELP) on the coagulation system.
Julius U; Siegert G; Gromeier S
Int J Artif Organs; 2000 Mar; 23(3):199-206. PubMed ID: 10795665
[TBL] [Abstract][Full Text] [Related]
4. Effects of different lipoprotein apheresis methods on serum protein levels.
Julius U; Siegert G; Kostka H; Schatz U; Hohenstein B
Atheroscler Suppl; 2015 May; 18():95-102. PubMed ID: 25936311
[TBL] [Abstract][Full Text] [Related]
5. Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP.
Julius U; Metzler W; Pietzsch J; Fassbender T; Klingel R
Int J Artif Organs; 2002 Dec; 25(12):1180-8. PubMed ID: 12518963
[TBL] [Abstract][Full Text] [Related]
6. Apheresis technologies for prevention and regression of atherosclerosis: clinical results.
Bambauer R; Schneidewind JM; Latza R
ASAIO J; 1999; 45(5):403-7. PubMed ID: 10503615
[TBL] [Abstract][Full Text] [Related]
7. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
Geiss HC; Otto C; Parhofer KG
Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of DALI-LDL-apheresis in two patients treated with the angiotensin II-receptor 1 antagonist losartan.
Bosch T; Wendler T
Ther Apher Dial; 2004 Aug; 8(4):269-74. PubMed ID: 15274676
[TBL] [Abstract][Full Text] [Related]
9. The Dresden Apheresis Center - experience with LDL apheresis and immunoadsorption.
Julius U; Tselmin S; Fischer S; Passauer J; Bornstein SR
Atheroscler Suppl; 2009 Dec; 10(5):12-6. PubMed ID: 20129367
[TBL] [Abstract][Full Text] [Related]
10. One year experience with a low density lipoprotein apheresis system.
Durst R; Rund D; Schurr D; Eliav O; Ben-Yehuda D; Shpizen S; Ben-Avi L; Schaap T; Pelz I; Leitersdorf E
Isr Med Assoc J; 2002 Sep; 4(9):677-80. PubMed ID: 12440228
[TBL] [Abstract][Full Text] [Related]
11. Direct adsorption of lipoproteins from whole blood by direct adsorption of lipoprotein apheresis: first experience in two hypercholesterolemic children.
Bayrakci US; Besbas N; Ozcebe O; Coskun T; Akgul E; Kutluk T; Bakkaloglu A
Ther Apher Dial; 2005 Dec; 9(6):469-72. PubMed ID: 16354278
[TBL] [Abstract][Full Text] [Related]
12. Direct adsorption of low-density lipoprotein and lipoprotein(a) from whole blood: results of the first clinical long-term multicenter study using DALI apheresis.
Bosch T; Lennertz A; Schenzle D; Dräger J;
J Clin Apher; 2002; 17(4):161-9. PubMed ID: 12494408
[TBL] [Abstract][Full Text] [Related]
13. The first results demonstrating efficiency and safety of a double-column whole blood method of LDL-apheresis.
Hequet O; Le QH; Rigal D; Mekhloufi F; Jaeger S; Sassolas A; Groisne L; Moulin P
Transfus Apher Sci; 2010 Feb; 42(1):3-10. PubMed ID: 19932056
[TBL] [Abstract][Full Text] [Related]
14. Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol--the role of LDL-apheresis.
McGowan MP
J Clin Lipidol; 2013; 7(3 Suppl):S21-6. PubMed ID: 23642325
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of DALI LDL-apheresis at high blood flow rates: a prospective multicenter study.
Wendler T; Schilling R; Lennertz A; Sodemann K; Kleophas W; Messner H; Riechers G; Wagner J; Keller C; Bosch T
J Clin Apher; 2003; 18(4):157-66. PubMed ID: 14699591
[TBL] [Abstract][Full Text] [Related]
16. The lipid- and lipoprotein- [LDL-Lp(a)] apheresis techniques. Updating.
Stefanutti C; Morozzi C; Perrone G; Di Giacomo S; Vivenzio A; D'Alessandri G
G Chir; 2012; 33(11-12):444-9. PubMed ID: 23140934
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia.
Otto C; Kern P; Bambauer R; Kallert S; Schwandt P; Parhofer KG
Artif Organs; 2003 Dec; 27(12):1116-22. PubMed ID: 14678426
[TBL] [Abstract][Full Text] [Related]
18. LDL-apheresis: indications and clinical experience in a tertiary cardiac centre.
Archontakis S; Pottle A; Hakim N; Ilsley C; Barbir M
Int J Clin Pract; 2007 Nov; 61(11):1834-42. PubMed ID: 17935547
[TBL] [Abstract][Full Text] [Related]
19. Heparin-free DALI LDL-apheresis in hyperlipidemic patients: efficacy, safety and biocompatibility.
Wendler T; Lennertz A; Heinemann O; Duhr C; Samtleben W; Bosch T
Int J Artif Organs; 2000 Oct; 23(10):710-7. PubMed ID: 11075902
[TBL] [Abstract][Full Text] [Related]
20. Contact activation in low-density lipoprotein apheresis systems.
Krieter DH; Steinke J; Kerkhoff M; Fink E; Lemke HD; Zingler C; Müller GA; Schuff-Werner P
Artif Organs; 2005 Jan; 29(1):47-52. PubMed ID: 15644083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
